Skip to main content
    T

    Trevi Therapeutics Inc (TRVI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.51
    +0.22 (+1.66%)

    Market Cap: $1.89B

    Last updated: Nov 17, 2026 at 4:20 PM ET

    Trevi Therapeutics Inc (TRVI) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Trevi Therapeutics (TRVI) has a market cap of $1.89B and an enterprise value of $1.87B. Revenue fell 100.00% over the last 12 months from the 12 months before. Its share count is up 10.08% from a year earlier.

    Total Valuation

    Enterprise value is 1.47% below the market cap, as cash exceeds debt.

    Market Cap$1.89B
    Enterprise Value$1.87B
    Latest price (Nov 17, 2026)$13.51

    Key Dates

    The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 15, 2027 (expected)
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.00% in the quarter ended Sep 30, 2026 and grew 25.58% a year over 2 years.

    Shares Outstanding159.73M
    Shares Change (YoY)+10.08%
    Shares Change (QoQ)+2.00%
    Share Count Growth (2Y CAGR)+25.58%

    Price Statistics

    The stock is up 18.82% over 52 weeks and trades 2.74% below its 50-day average.

    Beta (1Y)1.37
    52-Week Change+18.82%
    1-Month Change+13.53%
    3-Month Change-28.18%
    6-Month Change+2.04%
    5-Year Change+1054.04%
    Total Return (1Y)+18.82%
    Total Return (3Y CAGR)+113.37%
    Total Return (5Y CAGR)+67.39%
    Return vs SPY (1Y)+7.89%
    Max Drawdown (1Y)-39.08%
    Max Drawdown (3Y)-39.08%
    Sharpe Ratio (1Y)0.30
    Correlation with SPY (1Y)0.32
    50-Day Average$13.89
    200-Day Average$14.55
    52-Week Range$9.82 to $20.22
    RSI (14 Days)47.6
    Average Volume (20 Days)1.62M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 38.86x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio38.86x
    Quick Ratio38.86x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -20.07% over the last 12 months, against a 5-year average of -66.51%.

    Return on Equity (ROE)-20.07%
    Return on Assets (ROA)-19.55%
    ROE (5Y Average)-66.51%
    ROA (5Y Average)-41.95%
    ROIC (5Y Average)-49.14%

    Scores

    TRVI has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$31.00K
    Operating Income-$70.13M
    Pretax Income-$60.83M
    Net Income-$60.76M
    Reported EPS (TTM)-$0.39

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 97.41% of the $310.81M in total assets.

    Cash and Equivalents$27.85M
    Total Debt$0
    Net Cash$27.85M
    Net Cash Per Share$0.17
    Working Capital$297.93M
    Shareholder Equity$302.76M
    Book Value Per Share$1.90
    Total Assets$310.81M
    Total Liabilities$8.06M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $13.73M of capital spending, operating cash flow left -$75.16M of free cash flow.

    Operating Cash Flow-$61.44M
    Capital Expenditures$13.73M
    Free Cash Flow-$75.16M
    FCF Per Share-$0.53
    Depreciation and Amortization$2.56M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)+23.20%
    Tangible Book Per Share Growth (2Y CAGR)+23.20%

    Revenue and profit by year

    Dividends and Yields

    TRVI does not pay a dividend.

    Buyback Yield5.03%
    Shareholder Yield5.03%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About TRVI

    What is TRVI's market cap?

    Trevi Therapeutics has a market cap of $1.89B. Its enterprise value, which adds debt and subtracts cash, is $1.87B.

    How many shares of TRVI are outstanding?

    Trevi Therapeutics has 159.73M shares outstanding. The count is up 10.08% from a year earlier.

    Does TRVI pay a dividend?

    No. Trevi Therapeutics does not pay a dividend.

    How much debt does TRVI have?

    Trevi Therapeutics has $0 of total debt and $27.85M of cash and equivalents, a net cash position of $27.85M.